Alpha Sense BI

MAY 5, 2023

2023 so far has revealed ideal conditions for dealmaking due to valuation resets, lessened competition for deals, and new assets coming to market. M&A Trends by Industry Healthcare The COVID-19 pandemic ushered in a wave of unprecedented innovation, progress, and transformation to the healthcare industry in 2020.

Biotech 97

Biotech Capital Banking Startups 97

Alpha Sense BI

AUGUST 30, 2023

As time goes on and more firms adopt AI tools, these capabilities will become even more essential to maintain a competitive advantage. Intelligent Search : Algorithms and other AI technologies make every search smarter. Research shows that the AI in asset management market will grow at a staggering 34% CAGR through 2027.

Management 98

Management Biotech Due Diligence Algorithm 98

Alpha Sense BI

MARCH 13, 2024

billion acquisition of Carmot Therapeutics, a clinical-stage biotechnology company with three GLP-1 assets in clinical production, including its CT-388 lead GLP-1 asset, in the hopes of gaining a competitive footing among Novo Nordisk and Eli Lilly’s products currently on the market (Ozempic, Wegovy, and Mounjaro, respectively).

Pharmaceutical 59

Pharmaceutical Hospitals Due Diligence Biotech 59

Evalueserve

DECEMBER 6, 2021

Within the healthcare industry, healthcare equipment continues to outperform (refer to the graph below) driven by the urgent need for innovative care delivery in new or alternative settings and expedited recovery of demand especially for elective procedures. Sponsor deals rebounded exceptionally.

Capital 98

Capital Globalization Biotech Marketing 98

Alpha Sense BI

JANUARY 26, 2024

Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices—as well as their intentions to scale their digital health solutions—to the masses in hopes of securing capital. The post Key Takeaways from J.P.

Biotech 59

Biotech Research Loss Algorithm 59

Alpha Sense BI

NOVEMBER 7, 2023

The 10 initial drugs were chosen based on certain criteria set out by Medicare: they must be sold in pharmacies, not have substantial generic competition , and need to have been on the market for at least nine to 13 years for more complex biotech drugs. So, how could this become a problem for pharma companies in future QoQs?

Pharmaceutical 52

Pharmaceutical Biotech Innovation Technology 52

Engage3

MAY 19, 2022

Ken Ouimet, PhD Founder/Chairman, Technology Committee Ken Ouimet is the Chair of Strategic Planning and Founder of Engage3 and is credited with creating the retail revenue management and price optimization market. Fortune magazine listed Khimetrics as one of the 25 break-out innovative companies.

Retail 52

Retail Capital Finance Biotech 52

CIO

JULY 17, 2023

Many IT leaders today are focused more on security management as well as improving IT operations and systems performance than they are on top-line and strategic activities such as driving business innovation, identifying competitive differentiation opportunities, and even working on business strategy.

Biotech 567

Biotech Innovation Technology Technology 567